The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Interview with Doan Tran
Interview with Doan Tran, Process Development Scientist, Bayer Pharma, Germany
1. What is the reason behind the increased interest in continuous processing procedures? What are the main benefits?
As rules and regulations become more stringent and competition increases, continuous processing becomes necessary in order to ensure things are done right the first time. The greatest benefit of continuous processing is getting instant results, leading to better control over our processes before manufacturing is completed. Additionally, it increases process understanding and gives results for better decision making. Ultimately, this keeps a company competitive as it reduces time and cost.
2. Are all procedural steps designed and well established already? How far are we from the ideal construction?
We have PAT and QbD, which are relatively new to the pharmaceutical industry. I would say we are starting, but not yet at the ideal construction, if we are speaking of the industry as a whole. I believe it will take some time for the ideal construction to be reached.
3. How should this approach be implemented into the company practice? What are your experiences?
Implementation is difficult because many changes need to be made to documentation, equipment, state-of-the-art technology, etc. It’s best to change things gradually. Currently, we are facing many of these changes. We are not only ensuring continuous processing but also increasing knowledge. Due to continuous processing, we are able to decrease the time required for our processes, which can be used for more beneficial tasks, such as analyzing data, instead of constantly solving problems.
4. Is it relevant only for upstream professionals?
No, because continuous processing provides lean processes with an increase in results and knowledge; therefore, this procedure can flow downstream as we go about its implementation.
5. What are your research steps in the case of development of other fermentation techniques?
This is accomplished through seminars and other functions within the company, such as the technology group.
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?